RetaMaps

Alabama One Weight Loss Clinic

Alabama One Weight Loss Clinic · 750 Downtowner Loop West · Mobile, AL 36609

4.4· 36 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • Medically supervised weight loss

About this practice

Alabama One Weight Loss Clinic's Mobile, Alabama, office is at 750 Downtowner Loop West, Suite B, per its website, with clinic days on Tuesday, Wednesday and Thursday. The site, shared with its Brewton office, says the clinic offers diet plans and medications and references more than 25 years of operation. On Google the Mobile office has a 4.4-star rating across 36 reviews dating back to 2015, with 2 posted in the past year. Reviewers mention the staff most, in 13 reviews, followed by results and the team's knowledge.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsNot listed
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.4
Google rating · 36 reviews
2
reviews in the past year (avg ★ 5.0)
1
reviews mention GLP-1 medications
9
reviews mention weight loss

Counts computed by RetaMaps from public Google reviews; most recent review 2026-04-05. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★4.4 across 36 Google reviews. Of the 36 reviews we analyzed, 32 (89%) are positive (4–5★) and 4 (11%) are negative (1–2★).

What patients like

  • Friendly, helpful staff12 reviews
  • Weight-loss results5 reviews
  • Knowledgeable, professional providers4 reviews
  • Feeling listened to3 reviews

Common complaints

  • Staff or front-desk issues3 of 4 negative
5★
26
4★
6
3★
0
2★
0
1★
4

Most recent Google reviews

Donna H.★★★★★2026-04-05

Been seeing them on and off for years they are the best priced and the doctors are amazing!

Ashley C.★★★★★2026-01-31

The staff is very sweet & helpful.. I was in & out in no time.. The dr answers all questions & is very helpful with what you should eat and do.. I would recommend them to a family or friend..

Maria S.★★★★★2024-11-21

Love this place. Straight forward, no surprises. You are able to choose your plan. No pressure. I have lost 8 pounds in 3 weeks. My sugar is down, full of energy, sleep better. You have to follow the plan, eat health, watch calorie intake, exercise.

Michelle S.★★★★★2024-05-06

Very friendly. Genuinely seems concerned and wants you to lose weight.

LaTara★★★★★2023-05-22

GREAT HOSPITALITY!!!!!!!

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Nearby providers in Mobile

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs